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The presence of bilateral pulmonary nodules in lung cancer usually means distant metastases (M1a).1 We present an 
extraordinary example that challenged us to look beyond this 
classification, illustrating the potential benefits of a multidis-
ciplinary re-evaluation in such a case.
CASE REPORT
A 70-year-old male, former smoker, and current mara-
thon runner was diagnosed in September 2005 with a prob-
able squamous cell carcinoma of the right upper lobe (RUL) 
with (possible) small satellite lesions, a nodule in the right 
middle lobe (RML), and a nodular structure in the left upper 
lobe (LUL) on computed tomography (CT) scan, and 18-fluo-
rodeoxyglucose positron emission tomography (FDG-PET) 
scan. This was considered to be a primary lung cancer with 
intrapulmonary metastases (stage IV, histology confirmed). 
The patient received six cycles of chemotherapy doublet (cis-
platinum 150 mg on day 1 and gemcitabine 2000 mg on days 
1 and 8), which resulted in a slight reduction in size of the 
lesion in the RUL, and a clear reduction of the lesion in the 
LUL, although the RML remained unchanged (Fig. 1). Eleven 
months later, the lesion in the RUL increased in size. A second 
opinion was arranged.
After reviewing all data and images with repeated PET 
and CT, the possibility of multiple primary tumors was con-
sidered. A video-assisted thoracoscopy, diagnostic wedge 
excision of the LUL, and a transthoracic biopsy of the RUL 
were performed, revealing two papillary adenocarcinomas. A 
wedge excision of the RML, a lobectomy of the RUL, and 
mediastinal lymph-node dissection showed a 1.8-cm diam-
eter papillary adenocarcinoma of the LUL, a 3.3-cm diameter 
mixed papillary adenocarcinoma/adenocarcinoma in situ of 
the RUL, and a 1.1-cm diameter adenocarcinoma in situ of the 
RML, all radically resected. All nodes were negative. Array-
comparative genomic hybridization analysis revealed that all 
these lesions showed different patterns of gains and losses, 
consistent with three primary tumors (Fig. 2).2
In December 2007, a recurrence in the operation 
scar of the LUL, and a new abnormality in the left lower 
lobe (LLL) were observed on CT scan, both 18-FDG-PET 
positive. Diagnostic wedge excisions of the LUL and LLL 
and a mediastinal lymph-node dissection were performed. 
Pathological examination showed two invasive papillary 
adenocarcinomas (LUL and LLL of 1.5 cm and 0.6 cm 
diameter, respectively), with free resection margins, with-
out lymph-node metastases. The postoperative course was 
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FIGURE 1.  Computed tomography scan at time of first 
presentation and after six cycles of chemotherapy. A, Shows 
a reduction of the lesion in the right upper lobe. B, Shows an 
unchanged right middle lobe lesion. C, Shows a clear reduc-
tion of the left upper lobe lesion.
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uneventful. There have been no signs of recurrence since, 
and the patient has been alive and well for more than 6 years 
after the initial diagnosis.
COMMENT
The differentiation between intrapulmonary lung metasta-
ses and multiple synchronous primary lung cancers (MSPLCs) 
may make the prospects for an individual completely different—
treatment with either palliative or curative intent. Differentiation 
between the two requires histopathology and imaging. Separate 
primary lung tumors can easily be recognized when they are 
histologically different. In case of identical histological fea-
tures, genetic analyses such as array-comparative genomic 
hybridization analysis may be useful in the distinction between 
MSPLC and metastases.2 Imaging techniques such as 18-FDG-
PET, may be of help by calculating standardized uptake values. 
Standardized uptake values of the tumors might differ more in 
patients with second primary tumors than in those with meta-
static disease.3 Furthermore, the growth pattern, lobulized and 
spiculated aspect on CT may be of help.4
An aggressive surgical approach is justified in patients 
with MSPLC because node-negative disease, and the absence 
of distant metastases, may result in survival rates comparable 
with patients with isolated lung cancers.5 To avoid pulmonary 
insufficiency limited surgical procedures are preferred. However, 
the resection must be complete.2 Patients with MSPLC and 
node-negative disease should, therefore, be staged separately 
and if possible, treated as separate entities with curative intent.6
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FIGURE 2.  Results of array-comparative genomic hybrid-
ization analysis. Chromosomal rearrangements as detected 
by array-comparative genomic hybridization analysis for 
biopsies of tumor tissue are shown (tumor tissue: epithelium, 
no selection of invasive or in situ tumor parts). On the y 
axis is the log2 tumor to normal ratio and on the x axis the 
chromosomal position. Gray dots are an average of five-
array measurements, because a moving average of five was 
used for each of the three plots. Gains and losses are posi-
tive and negative log2 ratio, respectively. The quality of the 
three plots are variable, reflecting the use of formalin fixed 
paraffin embedded clinical material specimens. A, Wedge 
excision apex left upper lobe: papillary adenocarcinoma. B, 
Wedge excision right middle lobe: adenocarcinoma in situ. C, 
Lobectomy material of the right upper lobe: mixed papillary 
adenocarcinoma/adenocarcinoma in situ. Nontumor DNA of 
this patient served as reference for each tumor. The arrows 
and corresponding signs (++,+,N and C) show the most 
obvious patterns of gains and losses in the chromosomes 1, 
8, and X (number 23), with ++ representing a whole chro-
mosomal arm gain, + a partial chromosomal arm gain, N 
no chromosomal aberrations, and C complex chromosomal 
band of gains and losses. Plot B is of marginal quality and 
hence, difficult to interpret. However, as shown by the arrows 
in the three plots, differences in gains and losses can be 
observed. The first arrow indicates no chromosomal aberra-
tions in chromosome 1 in plot B versus a complex change 
in plot A and a partial arm gain in plot C. The second arrow 
also shows no chromosomal aberration of chromosome 8 
in plot B versus a complex change in plot A and a whole 
chromosomal arm gain in plot C. The third arrow indicates 
a gain of the entire X chromosome in plot B, much like the 
X-chromosome gain in the sample of plot C, in contrast with 
the partial X-chromosome gain in plot A. Gross chromo-
somal differences are thus detected in the sample of plot B 
despite the marginal quality, and it is therefore reasonable 
to conclude that these differences support the assumption 
of different tumor origins. All array data are available in the 
Gene Expression Omnibus database, under accession number 
GSE42377.
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